Company Overview

For personal use only IHL-675A Inflammatory Bowel Disease Problem Inflammation is a major contributing factor to inflammatory bowel disease. Many patients do not respond to current drug treatments. Solution IHL-675A targets two components of the inflammatory pathway by combining two anti-inflamamtory drugs, CBD and hydroxychloroquine sulfate. Incannex has demonstrated that IHL-675A reduced disease severity in an animal model of inflammatory bowel disease to a greater extent than either CBD or hydroxychloroquine sulfate alone. Clinical development status Asset IHL-675A Inflammatory Bowel Disease* Preclinical Incannex Phase 1 CT FDA IND # IHL-675A Australian clinical trial investigating safety and pharmacokinetics in healthy volunteers. FDA Phase 2 FDA Phase 3 Addressable Market US$20B+ 4.8% Global market size in 2021 Lead Assets ●●●●000000 (5) Anticipated Milestones Complete Phase 1 CT FDA Pre-IND meeting (5) https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment- Projected annual growth rate from 2021 to 2028 market#:-:text-The%20global%20inflammatory%20bowel%20disease, market%20over%20the%20forecast%20period (5) FDA IND Phase 2 CT 2023 Investor Presentation 23

View entire presentation